| DRUG | SUPPLIED | DOSE | COMMENTS |
|---|---|---|---|
| CISAPRIDE (Paeds) (Prepulsid) Mechanism of action: Gastrointestinal prokinetic; serotonin 5HT4 receptor agonist Ref: 44, 63, 199, 200 Last update: 2022-06-16 |
tablet: 5 mg, 10 mg oral liquid (BCCH): 1 mg/mL |
Children: 0.15-0.2 mg/kg/dose PO TID-QID 15-30 min. before meals. Maximum: 10 mg per dose or 0.8 mg/kg/day **Cisapride was removed from the Canadian Market in August 2000 due to the association between its use and serious cardiac arrhythmias and sudden cardiac deaths. Cisapride may be released by the Special Access Program of Health Canada to treat individual patients in which the benefits are determined to outweigh the risks. Physicians wanting to prescribe cisapride must apply to the Special Access Program |
Elevated plasma concentrations (either from high doses or drug interactions) may increase risk for adverse effects. The most important of these is QT interval prolongation and ventricular arrhythmias. Due to increased risk for cardiac adverse effects (QTc prolongation, cardiac arrest, and serious ventricular arrhythmias), do not use in children with co-existing cardiac disease, moderate or severe liver impairment, renal failure, significant electrolyte disturbances or are on QT prolonging drugs. Consider an ECG prior to initiation and during treatment for those at risk for QT prolongation. CYP3A4 substrate with many possible drug interactions, check with a pharmacist. **Cisapride was removed from the Canadian Market in August 2000 due to the association between its use and serious cardiac arrhythmias and sudden cardiac deaths. Cisapride may be released by the Special Access Program of Health Canada to treat individual patients in which the benefits are determined to outweigh the risks. Physicians wanting to prescribe cisapride must apply to the Special Access Program Standard Prescription: cisapride __mg PO __(frequency) 15 to 30 min before meals (__mg/kg/dose) |